278 related articles for article (PubMed ID: 33116407)
21. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
22. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice.
Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W
J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355
[TBL] [Abstract][Full Text] [Related]
23. Ellagic acid protects ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation and bone resorption.
Lin X; Yuan G; Li Z; Zhou M; Hu X; Song F; Shao S; Fu F; Zhao J; Xu J; Liu Q; Feng H
J Cell Physiol; 2020 Sep; 235(9):5951-5961. PubMed ID: 32026468
[TBL] [Abstract][Full Text] [Related]
24. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
25. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption.
Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY
Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279
[TBL] [Abstract][Full Text] [Related]
27. Anethole inhibits RANKL-induced osteoclastogenesis by downregulating ERK/AKT signaling and prevents ovariectomy-induced bone loss in vivo.
Qu H; Zhang Y; He R; Lin N; Wang C
Int Immunopharmacol; 2021 Nov; 100():108113. PubMed ID: 34530203
[TBL] [Abstract][Full Text] [Related]
28. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
[TBL] [Abstract][Full Text] [Related]
29. Melatonin Inhibits Osteoclastogenesis and Bone Loss in Ovariectomized Mice by Regulating PRMT1-Mediated Signaling.
Choi JH; Jang AR; Park MJ; Kim DI; Park JH
Endocrinology; 2021 Jun; 162(6):. PubMed ID: 33713122
[TBL] [Abstract][Full Text] [Related]
30. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
31. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
32. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
[TBL] [Abstract][Full Text] [Related]
33. Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway.
Wu L; Liang J; Li J; Xu Y; Chen J; Su Y; Xian Y; Wei J; Xu J; Zhao J; Liu Q; Yang Y
Eur J Pharmacol; 2022 May; 923():174908. PubMed ID: 35405113
[TBL] [Abstract][Full Text] [Related]
34. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
[TBL] [Abstract][Full Text] [Related]
35. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
36. Eriodicyol inhibits osteoclast differentiation and ovariectomy-induced bone loss in vivo.
Lee J; Noh AL; Zheng T; Kang JH; Yim M
Exp Cell Res; 2015 Dec; 339(2):380-8. PubMed ID: 26450448
[TBL] [Abstract][Full Text] [Related]
37. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
[TBL] [Abstract][Full Text] [Related]
38. Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice.
Lee EJ; Kim JL; Kim YH; Kang MK; Gong JH; Kang YH
Phytomedicine; 2014 Sep; 21(10):1208-15. PubMed ID: 24932975
[TBL] [Abstract][Full Text] [Related]
39. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
40. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
